chamber before dis-
charging the patient.
That's about the
same as last year.
Facilities that use it
love it. "Patients love
the convenience and
the reduced
expense," says an
Indiana ASC execu-
tive director. It
"decreases patient
noncompliance with
drops and the negative outcomes that this can have," says an
Oklahoma ASC administrator.
Others are not as pleased, though. Donald Lenz, ASN, clinical director
of the Eye Surgery Center of New Albany (Ind.), says his facility "identi-
fied an increase in rebound inflammation post-operatively" with the
dropless approach and discontinued it. Our Philadelphia surgeon wor-
ries that it's too invasive. "It involves either shoving a cannula through
the zonule or adding a pars plana injection."
And there's the ever-present element of cost. While patients make out
because they don't have to buy drops, the injections are expensive for
facilities and there's no reimbursement, says Ellen Lopez, RN, the
director of the Arizona Ophthalmic Outpatient Surgery facility in
Phoenix.
• Extended-release steroid. In February, the FDA approved Dexycu,
an extended-release dexamethasone for injection into the posterior
chamber following cataract surgery. A single injection of Dexycu
A U G U S T 2 0 1 8 • O U T PA T I E N T S U R G E R Y. N E T • 9 5
• PHACO-FREE FRAGMENTING Iantech's miLoop is a pen-like device that features a
thin filament loop that the surgeon uses to fragment the lens without phaco.
